ABSTRACT
Objetivo: Revisar y discutir la evidencia actual del uso de la metformina como herramienta terapéutica en enfermedades cutáneas. Diseño. Artículo original. Investigación cualitativa. Revisión narrativa. Emplazamiento: Aragón y Murcia, España. Participantes: Médicos Internos Residentes de Dermatología Médico-Quirúrgica y Venereología y de Atención Primaria y Comunitaria. Métodos: Se ha realizado una revisión narrativa utilizando la base de datos bibliográfica PubMed con fecha de búsqueda el 27 de enero de 2022. Resultados: La metformina ha demostrado ser efectiva en el tratamiento de dermatosis inflamatorias tales como el acné, hidrosadenitis supurativa, psoriasis y dermatitis de contacto alérgica. También ha demostrado propiedades antitumorales frente al carcinoma basocelular, carcinoma espinocelular y melanoma. De forma adicional, se ha descrito efectos beneficiosos del tratamiento adyuvante con metformina en pacientes con carcinoma basocelular que reciben terapia fotodinámica. En pacientes con dermatosis relacionadas con endocrinopatías tales como el hirsutismo, la acantosis nigricans y los xantomas eruptivos, el tratamiento con metformina ha demostrado efectividad terapéutica. El tratamiento tópico con metformina ha demostrado ser eficaz en el tratamiento del melasma. Finalmente se ha propuesto como un fármaco con propiedades antienvejecimiento cutáneo y favorecedoras de la cicatrización. Para ninguna de las indicaciones previamente descritas se han objetivado efectos adversos graves. Conclusiones: La metformina es un tratamiento efectivo y seguro en el esquema terapéutico de dermatosis inflamatorias, neoplasias cutáneas, dermatosis relacionadas con endocrinopatías, melasma, envejecimiento cutáneo y cicatrización.(AU)
Objetive: To review and discuss the current evidence of the use of metformin as a therapeutic tool in frequent skin diseases. Design: Original article. Qualitative research. Narrative review. Location: Aragon and Murcia, Spain. Participants: Resident Physicians. Dermatology and Primary Health Care. Method: A narrative review has been carried out using the PubMed bibliographic database, being the search date the 27th of January of 2022. Results: Metformin has proven to be effective in the treatment of inflammatory skin diseases such as acne, hidradenitis suppurativa, psoriasis and allergic contact dermatitis. It has also shown antitumor properties regarding basal cell carcinoma, squamous cell carcinoma and melanoma. Additionally, beneficial effects of adjuvant treatment with metformin have been described in patients with basal cell carcinoma receiving photodynamic therapy. In patients with endocrinology-related dermatosis such as hirsutism, acanthosis nigricans and eruptive xanthomas, treatment with metformin has demonstrated therapeutic effectiveness. Topical treatment with metformin has also been useful in the treatment of melasma. Finally, it has been proposed as a drug with anti-aging and wound-healing promoting properties. Severe adverse effects have not been observed for any of the previously described indications, being this a well-tolerated treatment. Conclusions: Metformin is an effective and safe adjuvant in the therapeutic scheme of various inflammatory dermatoses, skin neoplasms, endocrinology-related dermatosis, melasma, skin aging and wound healing processes.(AU)
Subject(s)
Humans , Male , Female , Metformin , Skin Diseases , Skin Diseases/diagnosis , Skin Diseases/etiology , Skin Diseases/drug therapy , Dermatology , Skin , Diabetes Mellitus, Type 2/drug therapy , Primary Health CareABSTRACT
OBJETIVE: To review and discuss the current evidence of the use of metformin as a therapeutic tool in frequent skin diseases. DESIGN: Original article. Qualitative research. Narrative review. LOCATION: Aragon and Murcia, Spain. PARTICIPANTS: Resident Physicians. Dermatology and Primary Health Care. METHOD: A narrative review has been carried out using the PubMed bibliographic database, being the search date the 27th of January of 2022. RESULTS: Metformin has proven to be effective in the treatment of inflammatory skin diseases such as acne, hidradenitis suppurativa, psoriasis and allergic contact dermatitis. It has also shown antitumor properties regarding basal cell carcinoma, squamous cell carcinoma and melanoma. Additionally, beneficial effects of adjuvant treatment with metformin have been described in patients with basal cell carcinoma receiving photodynamic therapy. In patients with endocrinology-related dermatosis such as hirsutism, acanthosis nigricans and eruptive xanthomas, treatment with metformin has demonstrated therapeutic effectiveness. Topical treatment with metformin has also been useful in the treatment of melasma. Finally, it has been proposed as a drug with anti-aging and wound-healing promoting properties. Severe adverse effects have not been observed for any of the previously described indications, being this a well-tolerated treatment. CONCLUSIONS: Metformin is an effective and safe adjuvant in the therapeutic scheme of various inflammatory dermatoses, skin neoplasms, endocrinology-related dermatosis, melasma, skin aging and wound healing processes.
Subject(s)
Dermatitis , Melanosis , Metformin , Skin Diseases , Humans , Melanosis/chemically induced , Melanosis/drug therapy , Metformin/therapeutic use , Skin Diseases/drug therapy , SpainSubject(s)
Leg Ulcer , Ulcer , Humans , Leg , Leg Ulcer/diagnosis , Leg Ulcer/etiology , Leg Ulcer/therapySubject(s)
Hyperemesis Gravidarum , Purpura , Female , Humans , Hyperemesis Gravidarum/complications , PregnancyABSTRACT
No disponible
Subject(s)
Humans , Female , Aged , Foot Dermatoses/diagnostic imaging , Ankle/diagnostic imagingABSTRACT
No disponible
Subject(s)
Humans , Female , Middle Aged , Hydroxychloroquine/adverse effects , Erythema Multiforme/chemically induced , Drug Hypersensitivity/complications , Coronavirus Infections/drug therapy , Hydroxychloroquine/administration & dosage , Erythema Multiforme/complications , Dermatitis/pathology , Pneumonia, Pneumocystis/complications , Coronavirus Infections/complications , Pneumonia, Viral/complications , Pneumonia, Viral/drug therapy , Drug Eruptions/complicationsSubject(s)
COVID-19/diagnosis , Coinfection/diagnosis , Mycoplasma pneumoniae/isolation & purification , Pneumonia, Mycoplasma/diagnosis , SARS-CoV-2/isolation & purification , Urticaria/diagnosis , Antibodies, Bacterial/immunology , Antibodies, Bacterial/isolation & purification , Antibodies, Viral/immunology , Antibodies, Viral/isolation & purification , COVID-19/blood , COVID-19/immunology , COVID-19/virology , COVID-19 Serological Testing , Child , Coinfection/blood , Coinfection/immunology , Coinfection/microbiology , Enzyme-Linked Immunosorbent Assay , False Positive Reactions , Humans , Immunoglobulin M/immunology , Immunoglobulin M/isolation & purification , Male , Middle Aged , Mycoplasma pneumoniae/immunology , Pneumonia, Mycoplasma/blood , Pneumonia, Mycoplasma/immunology , Pneumonia, Mycoplasma/microbiology , SARS-CoV-2/immunology , Skin/blood supply , Skin/microbiology , Urticaria/blood , Urticaria/immunology , Urticaria/microbiologyABSTRACT
No disponible
Subject(s)
Humans , Male , Adolescent , Acrodermatitis/virology , Ischemia/virology , Coronavirus Infections/diagnosis , Severe acute respiratory syndrome-related coronavirus/pathogenicity , Chilblains/diagnosis , Pruritus/diagnosis , Diagnosis, Differential , Headache/etiology , Arthralgia/etiology , Cough/etiology , Polymerase Chain Reaction/methodsSubject(s)
Antiviral Agents/adverse effects , Coronavirus Infections/drug therapy , Erythema Multiforme/chemically induced , Hydroxychloroquine/adverse effects , Pneumonia, Viral/drug therapy , Antiviral Agents/therapeutic use , Betacoronavirus , COVID-19 , Erythema Multiforme/diagnosis , Erythema Multiforme/pathology , Female , Humans , Hydroxychloroquine/therapeutic use , Middle Aged , Pandemics , SARS-CoV-2 , COVID-19 Drug TreatmentABSTRACT
No disponible
